Contribution of Moxifloxacin or Levofloxacin in Second-Line Regimens with or without Continuation of Pyrazinamide in Murine Tuberculosis

Por Ahmad, Zahoor, Tyagi, Sandeep, Minkowski, Austin, Peloquin, Charles A., Grosset, Jacques H., Nuermberger, Eric L.
Publicado em 2013

Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis

Por Tasneen, Rokeya, Williams, Kathy, Amoabeng, Opokua, Minkowski, Austin, Mdluli, Khisimuzi E., Upton, Anna M., Nuermberger, Eric L.
Publicado no Antimicrob Agents Chemother (2014)

Activity of the Fluoroquinolone DC-159a in the Initial and Continuation Phases of Treatment of Murine Tuberculosis

Por Ahmad, Zahoor, Minkowski, Austin, Peloquin, Charles A., Williams, Kathy N., Mdluli, Khisimuzi E., Grosset, Jacques H., Nuermberger, Eric L.
Publicado em 2011

Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis

Por Williams, Kathy, Minkowski, Austin, Amoabeng, Opokua, Peloquin, Charles A., Taylor, Dinesh, Andries, Koen, Wallis, Robert S., Mdluli, Khisimuzi E., Nuermberger, Eric L.
Publicado em 2012

Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis

Por Ahmad, Zahoor, Tyagi, Sandeep, Minkowski, Austin, Almeida, Deepak, Nuermberger, Eric L., Peck, Kaitlin M., Welch, John T., Baughn, Anthony D., Jacobs, Williams R., Grosset, Jacques H.
Publicado em 2012